Cresilon Inc. expands its medical technology portfolio with a compact version of its TRAUMAGEL hemostatic gel, designed to streamline trauma response for emergency personnel.
Cresilon launches TRAUMAGEL Next Generation, a new product that could strengthen its position in the hemostatic gel market.
Biotech firm Cresilon Inc. unveiled its next-generation TRAUMAGEL hemostatic gel, featuring a compact design tailored for first responders. The new product, set for a 2026 debut at EMS World, aims to improve field trauma care through enhanced portability and one-handed application.
The new design offers a smaller footprint and allows for easy, one-handed use, which is critical for first responders managing trauma in the field.